United Kingdom· GB-APID-45692811000001102
Lyfnua 45mg tablets
A gefapixant product containing gefapixant, registered in United Kingdom by Merck Sharp & Dohme (UK) Ltd. The same ATC class is registered in 13 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Gefapixant is registered in 13 of 19 countries.
Countries holding a registration under ATC R05DB29 (gefapixant), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Gefapixant · ATC R05DB29
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Gefapixant
- Manufacturer
- Merck Sharp & Dohme (UK) Ltd
- Country
- United Kingdom (GB)
- ATC code
- R05DB29
- ATC class
- Gefapixant
- Defined daily dose
- 90 mg, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin00191778023749
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Gefapixant in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLYFNUAMerck Sharp & Dohme B.V., Haarlem
- SwitzerlandLyfnua, FilmtablettenMSD Merck Sharp & Dohme AG
- FinlandLyfnuaMerck Sharp & Dohme B.V.
- FranceLYFNUA 45 mg, comprimé pelliculéMERCK SHARP & DOHME (PAYS-BAS)
- IrelandLYFNUA 45 mg Film-coated tabletMerck Sharp & Dohme BV,
- IcelandLyfnuaMerck Sharp & Dohme B.V.*
- NetherlandsLyfnua 45 mg filmomhulde tablettenMerck Sharp & Dohme B.V.
- NorwayLyfnuaMerck Sharp & Dohme B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lyfnua
- Liechtenstein · Lyfnua
- Norway · Lyfnua
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/aad2f543-26e0-4073-be25-0929e019eefc GET /v1/drugs/aad2f543-26e0-4073-be25-0929e019eefc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "45692811000001102",
"desc": "Lyfnua 45mg tablets (Merck Sharp & Dohme (UK) Ltd)",
"form": "Oral tablet",
"vpid": "45707911000001100",
"source": "dmd",
"vtm_id": "45702711000001104",
"strength": "45 mg",
"substance": "Gefapixant",
"ingredient": "Gefapixant citrate",
"supplier_code": "39306911000001106"
}See everything about gefapixant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.